Idenix Pharma could still launch partnership with Novartis, says Caris
After Idenix (IDIX) released top-line data for IDX-184, Caris thinks the results were not as good as expected, but the firm anticipates that trials in the fall should offer more favorable data. However, the firm still thinks that Novartis (NVS) may exercise its option to partner on the drug later this year and its maintains a Buy rating on Idenix.
Idenix Pharma downgraded to Market Perform from Outperform at JMP Securities
JMP Securities downgraded Idenix given near-term cash needs. :theflyonthewall.com
Market Data 
Markets 
AI
